Cryoport Inc Overview
Industry: Integrated Freight & Logistics
Sector: Industrials
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20C and -150C. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee. Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. Th Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Cryoport Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $5.6M (+25% YoY). Net loss was -$8.3M (from $108.9M). Adjusted EBITDA was $0.4M.
What changed
- Revenue +25% YoY to $5.6M.
- Net loss was -$8.3M (from $108.9M).
Guidance / outlook
We expect upcoming growth catalysts in our business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services, will drive us to new heights in market position, growth, and productivity,” concluded Mr.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan
Headline from Investing.com Nigeria: Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan.
Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan
Headline from Investing.com Canada: Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan.
Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan
Headline from Investing.com: Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan.
Cryoport, Inc. Q2 2026 Earnings Call Summary
Headline from Yahoo Finance: Cryoport, Inc. Q2 2026 Earnings Call Summary.
Earnings call transcript: Cryoport posts q2 2026 profit milestone, shares rise after hours
Headline from Investing.com Canada: Earnings call transcript: Cryoport posts q2 2026 profit milestone, shares rise after hours.
CryoPort Inc (CYRX) (Q2 2026) Earnings Call Highlights: Positive EBITDA Milestone and 15% ...
Headline from Yahoo Finance: CryoPort Inc (CYRX) (Q2 2026) Earnings Call Highlights: Positive EBITDA Milestone and 15% .
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.